Announcements Trials
Browse Landscape

Phase

Phase 1 5

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Conditions

Neoplasms 5Healthy Participants 5Breast Neoplasms 5Prostatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Venous Thromboembolism 2Solid Tumor, Adult 2Neoplasm Metastasis 2Healthy Volunteers 2Endometrial Neoplasms 2Colorectal Neoplasms 2Cardiovascular Diseases 2cMET-dysregulated Advanced Solid Tumors 1Venous Thrombosis 1TP53 Y220C Mutation 1Stroke 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rectal Neoplasms 1Pulmonary Embolism 1Prostatic Neoplasms, Castration-Resistant 1Precancerous Conditions 1Peripheral Nervous System Diseases 1Pain 1Ovarian Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Liver Cirrhosis 1Leiomyosarcoma 1

Interventions

Rosuvastatin Calcium 5capivasertib 2Digoxin 2sotorasib 1ibrutinib 1Midazolam 1Dextromethorphan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Healthy Participants × Rosuvastatin Calcium × Clear all
NCT07088913 2026-03-03

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants

AstraZeneca

Phase 1 Completed
20 enrolled

Healthy Participants

NCT06677957 2025-01-03

A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants

Genentech, Inc.

Phase 1 Completed
19 enrolled

Healthy Participants

NCT05395117 2023-12-13

A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin

AstraZeneca

Phase 1 Completed
32 enrolled

Healthy Participants

NCT05045638 2023-08-14

Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants

Amgen

Phase 1 Completed
13 enrolled 14 charts

Healthy Participants

NCT05708573 2023-04-14

Potential Drug Interaction Between ALXN2040 and Rosuvastatin

Alexion Pharmaceuticals, Inc.

Phase 1 Completed
20 enrolled

Healthy Participants

Data powered by HemOnc (CC BY 4.0) Colophon âš¡